Oncology Program
Cancer
ClinicalActive
Key Facts
About Shionogi
Shionogi Inc. is a global pharmaceutical company with over 140 years of experience in drug discovery and development, headquartered in Japan with significant US operations. The company specializes in addressing unmet medical needs through innovative treatments for infectious diseases, antivirals, and complex therapeutic areas. Shionogi has built strategic partnerships with industry, government agencies, and biotech companies to advance science with urgency, particularly in response to global health challenges like antimicrobial resistance and COVID-19. The company operates as a publicly traded entity with a strong commitment to ethical business practices and transparent operations.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Shared Antigen mRNA Cancer Vaccines | BioNTech | Phase 2 |
| Targeted Oncology Therapies | BioNTech | Phase 1/2 |
| ARGX-119 | Argenx | Phase 1 |
| Bmab (Bevacizumab) | Biocon | Approved |
| Ciforadenant (CPI-444) | Corvus Pharmaceuticals | Phase 1/2 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1 |
| tovecimig | Compass Therapeutics | Clinical |
| CTX-8371 | Compass Therapeutics | Clinical |
| XmAb 14045 | Xencor | Clinical |
| XmAb 13676 | Xencor | Clinical |
| Vibostolimab | Xencor | Clinical |
| PB272 (neratinib, intravenous) | Puma Biotechnology | Not Disclosed |